Mirati Therapeutics (MRTX) Tops Q1 EPS by 30c

Mirati Therapeutics (NASDAQ: MRTX) reported Q1 EPS of ($3.18), $0.30 better than the analyst estimate of ($3.48). Revenue for the quarter came in at $7.17 million versus the consensus estimate of $4.82 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance